AIX 9.01 ▲0.33% ALU 0.88 ▼-2.22% DN1 99.70 ▼-0.09% EMUCA 0.89 KIT 1.90 ▲0.00% KKC 2.11 ▲0.00% LF1 1.92 ▲0.79% MBG 0.14 ▲0.00% MRE 1.88 ▼-0.53% PCI 1.09 ▼-0.91% PCX 1.99 ▼-0.75% RF1 3.52 ▼-0.28% SET 2.14 ▼-0.47% TET 0.22 ▼-2.22% WMX 1.69 ▼-1.17% BST 0.30 ▲3.45% CTS 0.56 ▲1.82% EFR 0.00 ▲0.00% AIX 9.01 ▲0.33% ALU 0.88 ▼-2.22% DN1 99.70 ▼-0.09% EMUCA 0.89 KIT 1.90 ▲0.00% KKC 2.11 ▲0.00% LF1 1.92 ▲0.79% MBG 0.14 ▲0.00% MRE 1.88 ▼-0.53% PCI 1.09 ▼-0.91% PCX 1.99 ▼-0.75% RF1 3.52 ▼-0.28% SET 2.14 ▼-0.47% TET 0.22 ▼-2.22% WMX 1.69 ▼-1.17% BST 0.30 ▲3.45% CTS 0.56 ▲1.82% EFR 0.00 ▲0.00%

OCC Orthocell Limited

Healthcare · Biotechnology · website
$0.70
52wk 0.70 – 1.60
Overall
Value
Growth
Health
Quality
Momentum
Dividend
Price
About Orthocell Limited

Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia and internationally. It offers Ortho Autologous Chondrocyte Implantation, a cartilage cell therapy for treatment of articular cartilage defects in the knee and ankle; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental applications; and Remplir, a collagen scaffold used in peripheral nerve repair. The company also develops Collagen Medical Device platform products for nerve, tendon, and ligament repair; and Tendon Cell Therapy for rotator cuff and lateral epicondyle indications. Orthocell Limited was incorporated in 2006 and is headquartered in Murdoch, Australia.

Fundamental trends
Financial statements
Loading…
Key metrics
Market cap
$191.99M
P/E (trailing)
P/E (forward)
-26.11
EPS (trailing)
-0.05
Dividend yield
Payout ratio
0.0%
Beta
-0.07
EV / EBITDA
-9.37
Price / Book
4.64
ROE
-41.1%
Operating margin
-162.7%
Net margin
-133.8%
Total cash
$44.37M
Total debt
$510,603
Current ratio
9.17
Debt / Equity
0.01
Free cash flow
$-8.07M
Avg volume
332,383
Latest annual results (FY ending 30 Jun 2025)
  • Revenue$7.55M
  • Gross profit$4.80M
  • Operating income-$13.98M
  • Net income-$8.57M
  • Diluted EPS-0.04
  • Free cash flow-$9.04M
  • Net debt-$28.04M
Sector peers (Healthcare)
TickerMkt cap P/EScore
CSL $59.53B 14.0
RMD $43.89B 20.4
SIG $34.28B 59.4
FPH $20.25B 52.2
PME $17.21B 73.5
SHL $10.79B 19.7
RHC $10.13B 34.8
COH $7.90B 22.9